雲從科技(688327.SH):終止2023年度向特定對象發行A股股票事項並撤回申請文件
格隆匯8月6日丨雲從科技(688327.SH)公佈,公司於2024年8月6日召開第二屆董事會第二十一次會議,審議通過了《關於終止2023年度向特定對象發行A股股票事項並撤回申請文件的議案》,董事會同意終止公司2023年度向特定對象發行A股股票事項並撤回申請文件。鑑於公司2023年第一次臨時股東大會和2024年第一次臨時股東大會已授權董事會全權辦理2023年度向特定對象發行A股股票的有關事項,且該授權尚在有效期限內,故本次終止向特定對象發行A股股票事項無需提交公司股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.